Coming back to: A community side-effect dataset, with its response rate and biases

On the subject in the title: A community side-effect dataset, with its response rate and biases Working notes rather than a conclusion.

Posting the method first, because I know what the first three replies will otherwise be.

• Column: C18, 3.0 x 150 mm, 2.6 um
• Mobile phase: 0.1% TFA in water / 0.1% TFA in acetonitrile
• Gradient: 5% to 53% organic over 27 minutes
• Detection: 280 nm
• Injection: 20 uL
• Sample: retatrutide, reconstituted to 0.5 mg/mL, injected within an hour

The main peak integrates at 97.4% of total area. There is a small feature on the trailing edge that I cannot decide is a shoulder or a baseline artefact, and that is what I am actually asking about.

I read the opening post twice before replying, because I had assumed the opposite.

Community-collected datasets: some members have compiled datasets from their own experience and shared them. They are self-reported, unblinded, and therefore limited as evidence. But they show real patterns that people experience.

Collection methods: ask how the data were collected. Longitudinal tracking over months is stronger than retrospective recall. Prospective measurement (done while experiencing something) is stronger than memory afterward.

Limitations of datasets: all community-collected data has limitations. The population is self-selected (people in this community are not representative of all people using these compounds). Reporting bias is real (remarkable outcomes get reported; mundane outcomes do not).

Bias toward positive outcomes: datasets collected by members are biased toward people who found the compounds useful. People who did not respond do not return. People who had bad outcomes might have left the community.

Coming back to post #4, because the follow-up matters more than the original answer.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Temporal bias: older data in a dataset might reflect conditions (supplier, formulation, context) that have changed. Newer data is more current.

How to contribute: if you have longitudinal data you want to add, the format is simple: date, measurement, context. Contact the maintainer of the specific dataset.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Reproducibility: if sharing data, include enough context (compound, dose, timeframe, method) that someone reading it understands what it represents.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

post #11 is right about the mechanism and I think understates the practical bit.

Privacy: if contributing data, only share data you are comfortable making permanent and public. Once posted, data is persistent.

I read post #11 twice before replying, because I had assumed the opposite.

Combining data from different sources: datasets from this site are not directly comparable to published trials because the populations are different. They are worth reading separately, not merged together.

Using data in discussions: datasets are useful as reference points when someone claims something unusual. "I have not seen that reported in the data" is different from "that is impossible", but data gives you something to say.